Skip to main content
Article thumbnail
Location of Repository

Population Differences in Death Rates in HIV-Positive Patients with Tuberculosis.

By I Ciglenecki, J R Glynn, A Mwinga, B Ngwira, A Zumla, P E M Fine and A Nunn


SETTING: Randomised controlled clinical trial of Mycobacterium vaccae vaccination as an adjunct to anti-tuberculosis treatment in human immunodeficiency virus (HIV) positive patients with smear-positive tuberculosis (TB) in Lusaka, Zambia, and Karonga, Malawi. OBJECTIVE: To explain the difference in mortality between the two trial sites and to identify risk factors for death among HIV-positive patients with TB. DESIGN: Information on demographic, clinical, laboratory and radiographic characteristics was collected. Patients in Lusaka (667) and in Karonga (84) were followed up for an average of 1.56 years. Cox proportional hazard analyses were used to assess differences in survival between the two sites and to determine risk factors associated with mortality during and after anti-tuberculosis treatment. RESULTS: The case fatality rate was 14.7% in Lusaka and 21.4% in Karonga. The hazard ratio for death comparing Karonga to Lusaka was 1.47 (95% confidence interval [CI] 0.9-2.4) during treatment and 1.76 (95%CI 1.0-3.0) after treatment. This difference could be almost entirely explained by age and more advanced HIV disease among patients in Karonga. CONCLUSION: It is important to understand the reasons for population differences in mortality among patients with TB and HIV and to maximise efforts to reduce mortality

Publisher: International Union Against TB and Lung Disease
Year: 2007
OAI identifier:
Provided by: MSF Field Research

Suggested articles


  1. (2001). Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS
  2. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg
  3. (1998). Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis
  4. (1999). HIV and tuberculosis in rural sub-Saharan Africa: a cohort study with two year followup. Trans R Soc Trop Med Hyg
  5. (1997). HIV testing and tuberculosis treatment outcome in a rural district in Malawi. Trans R Soc Trop Med Hyg
  6. (1998). Measurement and determinants of tuberculosis outcome in Karonga District, Malawi. Bull World Health Organ
  7. (2004). Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency viruspositive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ
  8. (2002). Treatment results of DOTS in 1797 Sudanese tuberculosis patients with or without HIV co-infection. Int J Tuberc Lung Dis
  9. (1997). Tuberculosis and human immunodeficiency virus infection in west Burkina Faso: clinical presentation and clinical evolution. Int J Tuberc Lung Dis
  10. (1997). High mortality rates among patients with tuberculosis in Bangui, Central African Republic. Lancet
  11. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d’Ivoire. Lancet
  12. (2000). Factors associated with an increased case-fatality rate in HIV-infected and non-infected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.